Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial
Published Online: 2024-10-?
Journal: The Lancet Oncology•Publisher: Elsevier BV
Authors: Amir T Fathi•Amitava Mitra•Bradley Clegg•Brian M Linhares•Celine Berthon•Cristina Papayannidis•Daniel Corum•Eduardo Rodríguez-Arbolí•Eunice S Wang•Gary Schiller•Ghayas C Issa•Harris S Soifer•Harry P Erba•James M Foran•Jessica K Altman•Jolanta Grembecka•Joshua Ray•Julie Mackey Ahsan•Kristen Pettit•Kun Nie•Lionel Adès•Mael Heiblig•Maria R Baer•Marilyn Tabachri•Marina Kremyanskaya•Michael R Savona•Mithun Vinod Shah•Mollie Leoni•Mrinal M Patnaik•Olga Salamero•Pau Montesinos•Pierre Peterlin•Roland B Walter•Stephane DeBotton•Stephen Dale•Tomasz Cierpicki
